Researchers in this study aim to prove the safety and efficacy of radiofrequency ablation in the treatment of a carefully selected low-risk papillary thyroid microcarcinoma patient group.
Study Type
OBSERVATIONAL
Enrollment
27
Ultrasound-guided percutaneous radiofrequency ablation of T1N0M0 papillary thyroid microcarcinomas
Premier Med Egészségügyi- Oktató- és Kutatóintézet
Budapest, Hungary
The number of patients without clinical evidence of a tumor on ultrasound and cytology on the treatment site
We measure the number of patients without clinical evidence of a papillary thyroid microcarcinoma at the treatment site, evaluated with a (B-mode) ultrasound scan and a contrast-enhanced ultrasound scan of the whole tyroid and cytology reports from a fine needle aspiration from the site of the treatment at 24 months post-ablation.
Time frame: 24 months
Number of patients with adverse effects
Adverse effects measured during and after the procedure
Time frame: 24 months
Volume reduction ratio
Volume reduction ratio: The volume reduction (initial volume minus final volume) compared to the original post-ablation volume, times 100. Volumes are measured on ultrasound. Length, width and depth is determined using the longest diameters on 3 perpendicular planes. Volume is reported in mL, calculated using the ellipsoid volume formula: (length x width x depth) x 0.524.
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.